The global Anti-infective drugs Market is estimated to see healthy growth, pegged at a CAGR of ~10% during the forecast period 2020-2025. The widespread increase in the R&D efforts about the new drug development with high efficacy and potency against multi-drug-resistant micro-organisms will lead to industry growth. It is also expected that the new drug approvals will emphasize market growth during the forecast period. For instance, the Food and Drug Administration (FDA) approved drugs, such as Descovy by Gilead, to treat HIV-1 infection and Zepatier by Merck that aims for chronic Hepatitis C virus (HCV) genotypes 1 or 4 disorders in adults.
Companies have recently launched a panel of FDA-approved, modified antibiotics for their use in soft tissue infections and acute bacterial skin treatment; these drugs include Sivextro (Tedizolid), Orbactiv (Oritavancin), Dalvance (Dalbavancin), and Zevtera (Ceftobiprole). The high penetration of anti-infective drugs due to improved efficacy will be a crucial growth driver for the anti-infective agents market over the forecast period.
High growth factors such as rising infectious diseases and antimicrobial resistance prevalence to existing anti-infective agents are estimated to boost the consumption size in terms of value and volume. Moreover, escalating health-consciousness, the availability of diagnostics for infectious diseases, and avoidable risks associated with the early diagnosis are some of the factors projected to boost the growth. The anti-infective viral drugs witness robust growth as contagious illnesses continues to rise amidst changing weather patterns globally. The prevalence of diseases such as malaria, chikungunya, and Chagas disease is also expected to drive demand for the anti-infective drugs market in the coming years.
According to the World Health Organization (WHO), Vector-borne illnesses account for more than 700,000 deaths annually. Moreover, the disease also accounts for 17% of all the common infectious diseases. It affects about 3.9 billion people in almost 128 countries with the spread of dengue illnesses, and nearly 100 million cases are estimated each year.
Moreover, diseases such as malaria have also seen massive global prevention efforts each year. A foundation similar to the Melinda and Bill Gates foundation has highly invested in preventing or reduce the impact of Malaria, as it causes over 400,000 deaths each year. These significant global efforts are anticipated to drive the demand for anti-infective drugs worldwide.
Segmentation Overview of the Global Anti-Infective Drugs Market
The anti-infective drugs market has been segmented into Type, Antibacterial Drug Class, Route of Administration, and Distribution Channel. These major market segments are further categorized into various sub-segments to study the market in detail.
- By Type Outlook (Antibacterial, Antiviral, Antifungal)
- By Antibacterial Drug Class Outlook (Cephalosporins, Penicillin, Fluoroquinolones, Macrolides, Carbapenem, Others)
- By Route of Administration Outlook (Topical, Oral, IV, Others)
- By Distribution Channel Outlook (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, e-Commerce, Others)
Key Players Insights
Pfizer Inc., Bayer AG, Sanofi, GlaxoSmithKline plc., Merck & Co., Inc., Abbott, Novartis AG, Gilead Sciences, Inc., Johnson & Johnson Services Inc., Astellas Pharma Inc., and Bristol-Myers Squibb Company, among others, are some significant players included in the research study of the global anti-infective drugs market.